Cargando…

Associations between Normal Organs and Tumor Burden in Patients Imaged with Fibroblast Activation Protein Inhibitor-Directed Positron Emission Tomography

SIMPLE SUMMARY: Several radiolabeled fibroblast activation protein targeted inhibitors (FAPI) have been developed for molecular imaging and therapy. A potential correlation of radiotracer uptake in normal organs and extent of tumor burden may have consequences for a theranostic approach using ligand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kosmala, Aleksander, Serfling, Sebastian E., Dreher, Niklas, Lindner, Thomas, Schirbel, Andreas, Lapa, Constantin, Higuchi, Takahiro, Buck, Andreas K., Weich, Alexander, Werner, Rudolf A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179441/ https://www.ncbi.nlm.nih.gov/pubmed/35681588 http://dx.doi.org/10.3390/cancers14112609

Ejemplares similares

Molecular imaging of arterial fibroblast activation protein: association with calcified plaque burden and cardiovascular risk factors
por: Kosmala, Aleksander, et al.
Publicado: (2023)

Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [(68)Ga]Ga-PentixaFor PET/CT
por: Serfling, Sebastian E., et al.
Publicado: (2022)

Impact of (68)Ga-FAPI-04 PET/CT on Staging and Therapeutic Management in Patients With Digestive System Tumors
por: Kosmala, Aleksander, et al.
Publicado: (2023)

Somatostatin Receptor-Directed PET/CT for Therapeutic Decision-Making and Disease Control in Patients Affected With Small Cell Lung Cancer
por: Serfling, Sebastian E., et al.
Publicado: (2023)

Lymphoma-Sink Effect in Marginal Zone Lymphoma Based on CXCR4-Targeted Molecular Imaging
por: Kosmala, Aleksander, et al.
Publicado: (2023)

Interobserver Agreement Rates on C-X-C Motif Chemokine Receptor 4–Directed Molecular Imaging and Therapy
por: Hartrampf, Philipp E., et al.
Publicado: (2023)

CXCR4-targeted molecular imaging after severe SARS-Cov-2 infection
por: Lambertini, Alessandro, et al.
Publicado: (2022)

Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers
por: Weich, Alexander, et al.
Publicado: (2022)

A Voice From the Past: Rediscovering the Virchow Node With Prostate-specific Membrane Antigen-targeted (18)F-DCFPyL Positron Emission Tomography Imaging
por: Werner, Rudolf A., et al.
Publicado: (2018)

Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach
por: Werner, Rudolf A., et al.
Publicado: (2017)

Theranostics in Hematooncology
por: Buck, Andreas K., et al.
Publicado: (2023)

CXCR4-Directed Imaging in Solid Tumors
por: Werner, Rudolf A., et al.
Publicado: (2019)

CXCR4-targeted theranostics in oncology
por: Buck, Andreas K., et al.
Publicado: (2022)

Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2014)

In-Vivo Somatostatin-Receptor Expression in Small Cell Lung Cancer as a Prognostic Image Biomarker and Therapeutic Target
por: Şen, Feyza, et al.
Publicado: (2023)

CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas
por: Weich, Alexander, et al.
Publicado: (2021)

The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?
por: Werner, Rudolf A., et al.
Publicado: (2018)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)F]FDG PET/CT and MRI
por: Linz, Christian, et al.
Publicado: (2021)

The impact of (177)Lu-octreotide therapy on (99m)Tc-MAG3 clearance is not predictive for late nephropathy
por: Werner, Rudolf A., et al.
Publicado: (2016)

Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma
por: Serfling, Sebastian E., et al.
Publicado: (2022)

Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2016)

Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor–Directed Molecular Imaging and Therapy
por: Serfling, Sebastian E., et al.
Publicado: (2022)

Improved cancer detection in Waldeyer’s tonsillar ring by (68)Ga-FAPI PET/CT imaging
por: Serfling, S., et al.
Publicado: (2020)

High Interobserver Agreement on PSMA PET/CT Even in the Absence of Clinical Data
por: Bundschuh, Ralph A., et al.
Publicado: (2023)

Recent advances in radiotracers targeting norepinephrine transporter: structural development and radiolabeling improvements
por: Chen, Xinyu, et al.
Publicado: (2020)

Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications
por: Werner, Rudolf A., et al.
Publicado: (2018)

mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [(177)Lu]Lu-PSMA I&T during long-term follow-up
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Detection Rate of (68)Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy
por: Brumberg, Joachim, et al.
Publicado: (2020)

Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2014)

Early biochemical and radiographic response after one cycle of [(177)Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients
por: Cytawa, Wojciech, et al.
Publicado: (2023)

Accuracy of 18-F Fluorodeoxyglucose Positron Emission Tomographic/Computed Tomographic Imaging in Primary Staging of Squamous Cell Carcinoma of the Oral Cavity
por: Linz, Christian, et al.
Publicado: (2021)

Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma
por: Werner, Rudolf A., et al.
Publicado: (2022)

The Number of Frames on ECG-Gated (18)F-FDG Small Animal PET Has a Significant Impact on LV Systolic and Diastolic Functional Parameters
por: Eissler, Christoph, et al.
Publicado: (2021)

Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients
por: Lapa, Constantin, et al.
Publicado: (2018)

Volumetric and texture analysis of pretherapeutic (18)F-FDG PET can predict overall survival in medullary thyroid cancer patients treated with Vandetanib
por: Werner, Rudolf A., et al.
Publicado: (2018)

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Predicting Microenvironment in CXCR4- and FAP-Positive Solid Tumors—A Pan-Cancer Machine Learning Workflow for Theranostic Target Structures
por: Marquardt, André, et al.
Publicado: (2023)

Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging
por: Buder, Kristina, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ve24j9630bg789rinjsbunav2h